{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-261719","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.239431+00:00","generated_at":"2026-05-17T00:57:33.128738+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kyverna secures up to $150M debt facility from Oxford Finance; SPS data readout accelerated","bullets":["Non-dilutive term loan facility of up to $150M; initial draw of $25M on Nov 3, 2025.","Loan matures Oct 1, 2030; floating interest at 1M SOFR + 5.00% (floor 3.75%); interest-only to Nov 2028/2029.","Cash runway extended into 2027, supporting SPS BLA filing and MG Phase 3 trial.","Topline registrational Phase 2 SPS data now expected early 2026 (narrowed from 1H 2026); BLA filing 1H 2026.","MG Phase 3 enrollment to start by year-end 2025; updated Phase 2/3 data expected 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-261719","json":"https://secwatch.observer/filing/0001193125-25-261719.json","markdown":"https://secwatch.observer/filing/0001193125-25-261719.md","text":"https://secwatch.observer/filing/0001193125-25-261719.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000119312525261719/0001193125-25-261719-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000119312525261719/kytx-20251102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:57:33.128738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"30d59cead1c7d6d56a8bed7f4ddea380d50983d0","claim":"Kyverna Therapeutics, Inc. incurred term loan of up to $150.0 million with Oxford Finance LLC at a floating per annum rate equal to (a) the greater of (i) the 1-Month CME Term S maturing October 1, 2030.","evidence_excerpt":"from time to time party thereto. The Loan and Security Agreement provides a non-dilutive term loan facility (the “Loan Facility”) up to an aggregate principal amount of up to $150.0 million in multiple tranches, subject to certain conditions. The Loan Facility includes an initial tranche of $40.0 million and two additional tranches totaling $60.0 million, subject to","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1994702/000119312525261719/0001193125-25-261719-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"up to $150.0 million"},{"label":"Counterparty","value":"Oxford Finance LLC"},{"label":"Rate","value":"a floating per annum rate equal to (a) the greater of (i) the 1-Month CME Term S"},{"label":"Maturity","value":"October 1, 2030"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}